tbuckley/cabot-search huggingface dataset:
A Review of the Evidence for the Effectiveness, Safety, and Cost of Acupuncture, Massage Therapy, and Spinal Manipulation for Back Pain
Authors: Daniel C. Cherkin, Karen J. Sherman, Richard A. Deyo, Paul G. Shekelle
Journal: Annals of Internal Medicine (2003)

Background: Few treatments for back pain are supported by strong scientific evidence. Conventional treatments, although widely used, have had limited success. Dissatisfied patients have, therefore, turned to complementary and alternative medical therapies and providers for care for back pain. Purpose: To provide a rigorous and balanced summary of the best available evidence about the effectiveness, safety, and costs of the most popular complementary and alternative medical therapies used to treat back pain. Data Sources: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Study Selection: Systematic reviews of randomized, controlled trials (RCTs) that were published since 1995 and that evaluated acupuncture, massage therapy, or spinal manipulation for nonspecific back pain and RCTs published since the reviews were conducted. Data Extraction: Two authors independently extracted data from the reviews (including number of RCTs, type of back pain, quality assessment, and conclusions) and original articles (including type of pain, comparison treatments, sample size, outcomes, follow-up intervals, loss to follow-up, and authors' conclusions). Data Synthesis: Because the quality of the 20 RCTs that evaluated acupuncture was generally poor, the effectiveness of acupuncture for treating acute or chronic back pain is unclear. The three RCTs that evaluated massage reported that this therapy is effective for subacute and chronic back pain. A meta-regression analysis of the results of 26 RCTs evaluating spinal manipulation for acute and chronic back pain reported that spinal manipulation was superior to sham therapies and therapies judged to have no evidence of a benefit but was not superior to effective conventional treatments. Conclusions: Initial studies have found massage to be effective for persistent back pain. Spinal manipulation has small clinical benefits that are equivalent to those of other commonly used therapies. The effectiveness of acupuncture remains unclear. All of these treatments seem to be relatively safe. Preliminary evidence suggests that massage, but not acupuncture or spinal manipulation, may reduce the costs of care after an initial course of therapy.
Abstract 15006: The Associations Between Symptom Clusters and Quality of Life Trends Following Coronary Artery Bypass Surgeries in Taiwan
Authors: Ming Fen Tsai, Po-Jung Yuan, Feng-Chun Tsai, Tsuey-Yuan Huang
Journal: Circulation (2014)

Objectives: Patients undergoing coronary artery bypass surgery (CABS) often experience multiple symptoms concurrently following surgeries. Quality of life (QOL) has been an important outcome measurement in cardiac patients. Little is known on correlations between symptom clusters and trends of QOL among CABS patients within three months in Taiwan. The aims of the study are to identify cluster subgroups based on eight commonly seen symptoms and examine how these identified symptom cluster subgroups influenced QOL over time. Methods: A prospective correlational design with repeated measurement was used. Symptoms were measured by the Cardiac Symptom Survey at 1 week post-operatively. The SF-36 was administered at baseline, 6 weeks and 3 months post-operatively. A two-stage cluster analysis was conducted to identify subgroups of patients based on their perceived severity of the eight symptoms. Results: A total of 223 subjects from 6 medical centers were included. The result of cluster analysis showed a best s...
Langerhans cell deficiency in reticular dysgenesis
Authors: Jean-François Emile, Frédéric Geissmann, Oscar de la Calle Martin, Isabelle Radford-Weiss, Yves Lepelletier, Berno Heymer, Teresa Espanol, Ken B. de Santes, Yves Bertrand, Nicole Brousse, Jean-Laurent Casanova, Alain Fischer
Journal: Blood (2000)
A Pill for Every Ill
Authors: Lorna Swan
Journal: Circulation (2002)

A Pill for Every IllTo the Editor:Dr Lip 1 and The HOPE investigators 2 again sing the praises of ACE inhibitors ("the pill for every ill")-this time in the regression and prevention of ECG-LVH.The numerous "nonblood pressure" properties of ACE inhibition are elegantly described in Dr Lip's editorial, as the benefits noted were not simply explained by blood pressure reduction.However, the blood pressure story may not be quite dead yet.ACE inhibitors have a more favorable effect on central aortic pressure and pulsatile hemodynamics than other antihypertensive agents. 3End-organ damage is known to correlate with parameters of pulse wave morphology.The regression of carotid intima media thickness, for example, is closely correlated with regional reductions in pulse pressure. 4Pulse pressure, a marker of conduit vessel compliance, was a significant predictor of adverse cardiovascular events in both the SAVE (Survival And Ventricular Enlargement study) and SOLVD (Studies Of Left Ventricular Dysfunction) cohorts. 5CE inhibitors decrease wave reflection and pulse wave velocity and to focus solely on the effects these agents have on systolic and diastolic blood pressures fails to appreciate these important components.Loss of arterial wall compliance per se is a stimulus to the development of atheroma-yet another manifestation of end-organ damage.It may well be that the "additional" benefits of ACE inhibitors are due to these beneficial changes in central aortic pulsatility.Examination of pulse pressure, or carotid pressure by tonometry, opens up yet another area of interest in these impressive drugs.
SPUTUM STUDIES IN PNEUMONIA: THE SELECTION OF THERAPY
Authors: Arthur W. Frisch, Alvin E. Price
Journal: Annals of Internal Medicine (1941)

Article1 December 1941SPUTUM STUDIES IN PNEUMONIA: THE SELECTION OF THERAPYARTHUR W. FRISCH, M.D., ALVIN E. PRICE, M.D., F.A.C.P.ARTHUR W. FRISCH, M.D.Search for more papers by this author, ALVIN E. PRICE, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-15-6-987 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDuring the past few years the sulfonamide drugs have proved to be so effective that they have largely supplanted serum in the treatment of pneumococcic pneumonia. Some clinicians, however, use both forms of medication either simultaneously in critically ill patients or separately in the event of failure of one agent alone. Because of the known differences in the mode of action of serum and chemotherapy, and because of variations in the severity of different cases, it would seem desirable to individualize specific treatment if some satisfactory criterion was available which would indicate the exact status of each patient. During the...Bibliography1. FRISCH AW: Sputum studies in pneumonia as an aid in prognosis, Am. Jr. Clin. Path., 1940, x, 472. CrossrefGoogle Scholar2. FRISCH AW: Sputum studies in lobar pneumonia: phagocytosis and the effect of serum therapy, Proc. Soc. Exper. Biol. and Med., 1938, xxxix, 473. CrossrefGoogle Scholar3. FRISCH AW: Clumping of extracellular encapsulated pneumococci in sputum for control of serum therapy, Proc. Soc. Exper. Biol. and Med., 1939, xl, 495. CrossrefGoogle Scholar4. FRISCH AW: Sputum studies in pneumonia: the effect of sulfanilamide, Jr. Lab. and Clin. Med., 1940, xxv, 361. Google Scholar5. FRISCH AW: Sputum studies in pneumonia: the effect of sulfapyridine and sulfathiazole, Am. Jr. Clin. Path., in press. Google Scholar6. FRISCHPRICE AWAE: Sputum studies in pneumonia: therapy and prognosis, Detroit Med. News, Wayne University Educational Issue No. 1, 1941, xxxii, 20. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Detroit, Michigan*Received for publication May 22, 1941.Departments of Bacteriology and Internal Medicine, Wayne University College of Medicine, Detroit, Michigan.Supported by a grant from the Commonwealth Fund to the Michigan Department of Health Laboratories. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byModern Treatment of Pneumonia* 1 December 1941Volume 15, Issue 6Page: 987-993KeywordsBacteriologyChemotherapyDrugsPneumoniaSputumSulfonamide ePublished: 1 December 2008 Issue Published: 1 December 1941 PDF downloadLoading ...
Abstract 18268: When is Left Ventricular Function Too Poor for Successful Aortic Valve Replacement? Analysis of 3,075 Cases
Authors: Dai Une, Vincent Chan, Laura Mesana, Michelle Maklin, Ryan Chan, Ian Burwash, Roy G Masters, Thierry G Mesana, Marc Ruel
Journal: Circulation (2014)

Introduction:  Preoperative left ventricular (LV) dysfunction often improves after aortic valve replacement (AVR) due to relief of pressure or volume overload; however, LV function sometimes remains unimproved. We sought to determine the predictors of unimproved LV function after AVR, and its effects on clinical outcomes.   Methods:  A total of 3,075 patients who underwent surgical AVR (without concomitant mitral surgery) were longitudinally assessed in a follow-up clinic and with echocardiography (median follow-up 6.5yrs). At operation, mean age was 67.8±13.5yrs, 32% were female, and 29% had preoperative LV dysfunction (defined as: grade II, ejection fraction 35-49%; grade III, 20-34%; grade IV,    Results:  Actuarial survival at 15yrs was 62.0±2.4, 47.8±4.6, 40.7±5.7, and 34.9±8.0% ( P  P =0.005) (Figure). Unimproved LV dysfunction was predicted by higher preoperative LV diastolic diameter (OR 1.9 per cm;  P  P =0.003), and older age (OR 1.3 per 10yrs;  P =0.026). Notably, in patients with LV diastolic diameter≥55mm, the incidence of death or unimproved LV dysfunction at 2yrs was 55.1% ( P    Conclusions:  Unimproved LV dysfunction after AVR is a strong risk factor for decreased long-term survival. Older age, LV dilatation, and a low preoperative aortic valve gradient are significant risk factors for unimproved LV dysfunction and death, especially in those with LV diastolic diameter≥55mm.
Zinc sulphate: a new concept of treatment of erythropoietic protoporphyria
Authors: A.B. Petersen, P.A. Philipsen, H.C. Wulf
Journal: British Journal of Dermatology (2011)

Funding sources: no external funding. Conflicts of interest: none declared. Madam, Erythropoietic protoporphyria (EPP) is an inherited disorder of haem biosynthesis. Partial deficiency of ferrochelatase (FECH) causes accumulation of the photosensitizer protoporphyrin IX (PpIX) and production of reactive oxygen species (ROS) upon light exposure, resulting in acute cutaneous photosensitivity such as painful burning sensations, itching, pruritus and oedema in the skin owing to light or sun exposure. Treatment with antioxidants (beta‐carotene, vitamin C, N‐acetyl cysteine) has been tried with diverging results.1 Mild anaemia or iron deficiency is frequent in patients with EPP.2 Oral iron treatment has been reported to exacerbate the symptoms,3, 4 which has also been the case among our patients with EPP. We therefore hypothesized that decreased absorption of iron from the gastrointestinal tract might be of benefit to patients with EPP. As zinc can impair the intestinal absorption of ferrous iron by a dose‐dependent competitive interaction between inorganic zinc and nonhaem iron,5, 6 zinc was a possible candidate of choice for a decrease of iron uptake.
Abstract 13324: Single Ascending Dose Pharmacokinetics and Pharmacodynamics of MDCO-216 (ApoA-I Milano/POPC) in Healthy Volunteers
Authors: S. Eralp Bellibas, David Kallend, Alain Bobillier, Herman Kempen, Peter L Wijngaard
Journal: Circulation (2014)

Introduction: MDCO-216, a complex of dimeric recombinant apolipoprotein A-I Milano (apoA-I M) and a phospholipid (POPC), is currently under development to improve cardiovascular outcomes by reducing plaque burden in patients with atherosclerotic disease. An earlier version of MDCO-216 has been shown to reduce atherosclerotic plaque burden in animal models and in patients with ACS. The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of newly manufactured MDCO-216 first time in healthy volunteers. Methods: 24 healthy volunteers received a single dose of MDCO-216 (5, 10, 20, 30 or 40 mg/kg) or placebo (in 2:1 ratio) as a 2 hour IV infusion in a double-blind, randomised design. Serial blood samples were collected for PK and anti-drug Ab (ADA) analysis. An ex-vivo cholesterol efflux assay was used as one of several exploratory PD biomarkers for MDCO-216 activity. Results: No ADA was detected with any dose at any time point. Plasma mean T 1/2 of MDCO-216 ranged from 48 to 61 hours (56 hr. in average) and median T max ranged between 2 to 4 hours. No obvious difference in CL was observed with increases in dose and ranged from 0.62 to 0.98 mL/hr/kg. Exposure parameters increased with dose in a slightly less than dose-proportional manner with a range of 138 to 794 μg/mL for C max and 3391 to 20788 μg.hr/mL for AUC 0-48 . Dose-dependent increases in ABCA1-mediated efflux capacity of up to 4-fold above baseline and smaller increases of SRB1-mediated efflux capacity occurred rapidly after infusion at all doses. The dose-response analysis for ABCA1-mediated efflux best fitted into a sigmoid E max (maximum effect) PD model and predicts an E max of 15.6% which saturates around a 30 mg/kg dose of MDCO-216. Conclusions: This data demonstrate that MDCO-216 can profoundly stimulate the first step of reverse cholesterol transport at clinically achievable doses with a predictable PK/PD profile.
Colour Atlas of Paediatric Haematology
Authors: Ian M. Hann
Journal: Annals of Internal Medicine (1991)

Normal appearances congential red cell disorders acquired and secondary red cell disorders disorders and polymorphonuclear leucocytes disorders of lymphocytes platelet disorders acute lymphoblastic leukaemia acute non-lymphoblastic leukaemia myeloproliferative disorders histiomonocytic disorders lymphomas other tumours aplastic anaemia neonatal and perinatal disorders parasites and opportunistic infections storage disorders artefacts. Appendices: normal haematological values in infancy and childhood revised criteria for the classification of AML the Franco-American-British (FAB) classifiacation of myelodysplastic syndromes the FAB scorin system for L1 and L2 ALL.
ONCHOCERCIASIS: CASE REPORT
Authors: Joseph M. Gannon
Journal: Annals of Internal Medicine (1947)

Case Reports1 February 1947ONCHOCERCIASIS: CASE REPORTJOSEPH M. GANNONJOSEPH M. GANNONSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-26-2-287 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOnchocerciasis is a tropical disease found only in sharply circumscribed areas of Central America and Africa. It is characterized by the occurrence of subcutaneous tumors or nodules due to the presence of the nematode Onchocerca volvulus. The disease is virtually confined to the colored race. Stitt1 reports that in Africa infection in white men is rare, only some 20 cases having been reported. The case here presented occurred in a white male and the diagnosis was made while he was a patient in a hospital in England.CASE REPORTA 32 year old, white, Free French sergeant was wounded in...Bibliography1. STRONG RP: Stitt's diagnosis, prevention, and treatment of tropical diseases, 6th Edition, 1942, The Blakiston Co., Philadelphia. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication September 21, 1945. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1947Volume 26, Issue 2Page: 287-290KeywordsRacial and ethnic issuesTropical diseases ePublished: 1 December 2008 Issue Published: 1 February 1947 PDF downloadLoading ...
METABOLIC ANTAGONISM BETWEEN AN AZO DYE AND RIBOFLAVIN: EFFECT OF 3'-METHYL-4-MONOMETHYLAMINOAZOBENZENE ON MUTANTS OF NEUROSPORA CRASSA.
Authors: David A. Salzberg
Journal: Cancer Research (1964)

Summary  Studies have been made on the effect of carcinogenic azo dyes, 3′-methyl-4-dimethylaminoazobenzene and 3′-methyl-4-monomethylaminoazobenzene, on various strains of  Neurospora crassa , including riboflavin-, adenine-, choline-, methionine-, lysine-, and isoleucine-valine-deficient mutants. The capacity of riboflavin to restore growth for the riboflavin mutants which were inhibited by azo dye has indicated the existence of metabolic antagonism between riboflavin and the dye. This azo dyeriboflavin inhibition in Neurospora has given rise to the suggestion that some similar dye-vitamin relationship may exist in liver cells of rats which are fed azo dye. The protective effects of riboflavin-enriched diets, as well as the lowering of riboflavin content in livers of rats fed the dye, might thus be accounted for. Inhibition at a given level of 3′-methyl-4-monomethylaminoazobenzene occurred in varying degrees in each of the riboflavin-independent mutants, but all were consistent in being inhibited least or not at all by the dye at suboptimal concentrations of their required nutrient. Inhibition due to a given concentration of 3′-methyl-4-monomethylaminoazobenzene increased as concentrations of the required nutrient were raised as much as tenfold over the optimal concentration. This nonspecific inhibition was not affected by the addition of riboflavin to the medium and is in marked contrast to the behavior of the riboflavin-requiring strains, where inhibition caused by dye was greatest at lowest riboflavin concentrations and could be almost completely prevented by excess riboflavin.
Abstract 1916: β3 integrin/KRAS/RalB complex drives tumor stemness and resistance to EGFR inhibition
Authors: Laetitia Jocelyne Seguin, Shumei Kato, Aleksandra Franovic, Maria Fernanda Camargo, Katrhyn Elliott, Mayra Yebra, Jacqueline Lesperance, Ainhoa Mielgo, Jay Desgrosellier, Sudarshan Anand, Sara Weis, David Cheresh
Journal: Cancer Research (2014)

Abstract Integrin αvβ3 expression is a marker of tumor progression for a wide range of histologically distinct cancers, yet the molecular mechanism by which αvβ3 influences the growth and malignancy of cancer is poorly understood. Here, we reveal that integrin αvβ3, in the unligated state on lung, breast and pancreatic cancer cells, recruits KRAS and RalB to the plasma membrane, leading to the activation of TBK-1/c-Rel. These events are both necessary and sufficient to promote tumor initiation, anchorage-independence, self-renewal, as well as resistance to nutrient deprivation and treatment with receptor tyrosine kinase (RTK) inhibitors such as erlotinib. Genetic or pharmacological inhibition of RalB or its effectors suppress tumor initiation, self-renewal, and re-sensitizes tumors to RTK inhibition. These findings not only identify ανβ3 as a marker/driver of tumor stemness but also provide a strategy to overcome tumor resistance to RTK Inhibition. Citation Format: Laetitia Jocelyne Seguin, Shumei Kato, Aleksandra Franovic, Maria Fernanda Camargo, Katrhyn Elliott, Mayra Yebra, Jacqueline Lesperance, Ainhoa Mielgo, Jay Desgrosellier, Sudarshan Anand, Sara Weis, David Cheresh. β3 integrin/KRAS/RalB complex drives tumor stemness and resistance to EGFR inhibition. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1916. doi:10.1158/1538-7445.AM2014-1916
Fortnightly Review: The pneumococcal problem
Authors: S K Obaro, M A Monteil, D C Henderson
Journal: BMJ (1996)

<h3>Summary points</h3> Mortality from bacteraemic pneumonia has remained unchanged at 25% over the last 40 years Globally, Streptococcus pneumoniae causes over 1 million deaths in children under the age of 5 years Antibiotic resistant strains of S pneumoniae are increasing world wide. In Spain over 50% of isolates are resistant to one or more antibiotics Patients at increased risk of severe pneumococcal infection should be:
The Criminal: His Personnel and Environment. A Scientific Study.
Authors: August Drähms
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy
Authors: T. Saarne, T. Neimert-Andersson, H. Grönlund, M. Jutel, G. Gafvelin, M. van Hage
Journal: Allergy (2010)

To cite this article: Saarne T, Neimert-Andersson T, Grönlund H, Jutel M, Gafvelin G, van Hage M. Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy. Allergy 2011; 66: 255–263. Background: A hypoallergen of the major cat allergen Fel d 1, recombinant (r) Fel d 1 (DTE III), was previously shown to have retained T-cell reactivity and strongly reduced IgE-binding capacity compared to unmodified rFel d 1. Here, we evaluated the therapeutic capacity of rFel d 1 (DTE III) in a mouse model for cat allergy. Methods: Mice were subcutaneously (s.c.) sensitized with rFel d 1 and subsequently treated (s.c.) with 50 or 200 μg rFel d 1 (DTE III), or 50 μg rFel d 1, prior to intranasal challenge with cat dander extract. Airway hyperreactivity (AHR), cells and cytokines in bronchoalveolar lavage fluid, splenocyte in vitro response, and serum immunoglobulins were analyzed. Seven cat-allergic patients and ten healthy controls were tested for skin prick test (SPT) reactivity to rFel d 1 (DTE III) and rFel d 1. Results: Mice treated with 50 and 200 μg rFel d 1 (DTE III), and 50 μg rFel d 1, produced increased serum levels of rFel d 1-specific IgG1 and IgG2a compared to sham-treated mice. IgG from all treatment groups could block binding of patients' IgE to rFel d 1. The 200 μg rFel d 1 (DTE III) treatment tended to reduce AHR. All mice tolerated treatment with rFel d 1 (DTE III), in contrast to only four of ten treated with rFel d 1. Compared to rFel d 1, the hypoallergen showed a tendency of reduced SPT reactivity. Conclusion: The rFel d 1 (DTE III) hypoallergen might be a promising candidate for application in immunotherapy of cat allergy with improved safety and efficacy.